Research Topics
| Nigel S KeySummaryAffiliation: University of Minnesota Country: USA Publications
| Collaborators
|
Detail Information
Publications
Hyperhomocyst(e)inemia and ThrombophiliaNigel S Key
Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis 55455, USA
Arch Pathol Lab Med 126:1367-75. 2002..To review the role of an elevated total plasma homocysteine level (hyperhomocyst[e]inemia) in patients with venous or arterial thrombosis, as reflected by the medical literature and the consensus opinion of recognized experts in the field...- Diagnostic approaches to bleeding disordersNigel S Key
University of Minnesota Medical School, Minnesota, Minneapolis, USA
Hematology 10:29-32. 2005 - Coagulation inhibition for sepsisNigel S Key
Department of Medicine, University of Minnesota Medical School, 480 Mayo Building, 420 Delaware St SE, Minneapolis, MN 55455, USA
Curr Opin Hematol 9:416-21. 2002.... - Inhibitors in congenital coagulation disordersNigel S Key
University of Minnesota Medical School, Minneapolis, MN, USA
Br J Haematol 127:379-91. 2004..An attempt has been made to focus on recent advances in the immunology of inhibitors, and to speculate on their potential clinical application... - A 'touch' of the White platelet syndromeJames G White
Department of Laboratory Medicine, University of Minnesota, Minneapolis, MN 55455, USA
Platelets 16:346-61. 2005..Genetic studies to determine if this is the case are currently in progress... 
Tissue factor promotes activation of coagulation and inflammation in a mouse model of sickle cell diseasePichika Chantrathammachart
Division of Hematology Oncology, Department of Medicine, University of North Carolina at Chapel Hill, NC 27599, USA
Blood 120:636-46. 2012..Furthermore, it appears that TF contributes to these processes without affecting intravascular hemolysis...- Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancerJian guo Wang
Division of Hematology Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Blood 119:5543-52. 2012..The results of the present study using a xenograft mouse model suggest that tumor TF activates coagulation, whereas TF on circulating MPs may trigger venous thrombosis... - PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRIRaj S Kasthuri
Division of Hematology and Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Blood 119:5285-93. 2012..Our data suggest that monocyte TF may contribute to the development of thrombosis in patients with HIT... - Variant hemoglobin phenotypes may account for differential erythropoiesis-stimulating agent dosing in African-American hemodialysis patientsVimal K Derebail
Division of Nephrology and Hypertension, Department of Medicine, UNC Kidney Center, University of North Carolina at Chapel Hill, CB 7155, Chapel Hill, North Carolina 27599, USA
Kidney Int 80:992-9. 2011..Hence, our findings may explain, in part, the difference in ESA dosing between Caucasians and African-Americans with end-stage renal disease but await further study... 
Anthracycline treatment of the human monocytic leukemia cell line THP-1 increases phosphatidylserine exposure and tissue factor activityJeremiah C Boles
Department of Medicine, Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
Thromb Res 129:197-203. 2012..Malignancy conveys an increased risk for thrombosis and chemotherapy further elevates this risk. The pathophysiological mechanisms underlying this process remain poorly defined...- Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemiaOmer Aras
Departments of Medicine (Hematology, Oncology and Transplantation) and Vascular Biology Center, University of Minnesota Medical School, 420 Delaware Street SE, Minneapolis, MN 55455, USA
Blood 103:4545-53. 2004..MP-associated TF PCA was highly correlated with whole-blood TF PCA and total number of circulating MPs, and whole-blood TF PCA was highly correlated with TF mRNA levels... - Blood outgrowth endothelial cells as a vehicle for transgene expression of hepatocyte-secreted proteins via Sleeping BeautyBetsy T Kren
Department of Medicine, University of Minnesota Medical School, 420 Delaware Street SE, Minneapolis, MN 55455, USA
Endothelium 14:97-104. 2007..Thus, BOECs have the potential to provide clinically relevant secreted proteins for diseases other than those of endothelial origin... - Response of factor VIII and IX-deficient blood to wild type and high membrane affinity mutant factor VIIa in an in vitro whole blood clotting assay: possible correlation to clinical outcomeNicole Henderson
Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, St Paul 55108, USA
Thromb Haemost 88:98-103. 2002..The results may justify larger studies to determine the utility of this assay for evaluation of patient responsiveness and to set factor VIIa therapy levels... - Clinical and laboratory management of the prothrombin G20210A mutationRonald C McGlennen
Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, USA
Arch Pathol Lab Med 126:1319-25. 2002..DAT SOURCES: Review of the medical literature, primarily since 1996... - Views on methods for monitoring recombinant factor VIIa in inhibitor patientsNigel S Key
Department of Medicine, Divisionof Hematology, University of Minnesota, MN, USA
Semin Hematol 41:51-4. 2004..To date, however, no assay endpoint has been developed that can correlate accurately with clinical outcomes in a sufficiently large patient sample... - Analysis of tissue factor positive microparticlesNigel S Key
Department of Medicine, Division of Hematology Oncology, University of North Carolina at Chapel Hill, NC 27599, USA
Thromb Res 125:S42-5. 2010..Heterogeneity of TF-bearing MPs, such as the variable co-expression of surface phosphatidylserine, may determine not only their procoagulant potential, but also additional properties including rate of clearance from the circulation... - The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory statesJian-Guo Wang
Hematology, Oncology, and Transplantation Section, Department of Medicine, and the Vascular Biology Center, University of Minnesota, Minneapolis, USA
Blood 107:558-65. 2006.... - Postoperative coagulopathy in a pediatric patient after exposure to bovine topical thrombinSheri S Crow
Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota 55455, USA
Ann Thorac Surg 83:1547-9. 2007..This case report alerts pediatric providers to consider these inhibitors when postoperative coagulopathy occurs. Potential treatment options are reviewed... - Stored platelets contain residual amounts of tissue factor: evidence from studies on platelet concentrates stored for prolonged periodsSilvia Perez-Pujol
Department of Medicine and Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA
Transfusion 45:572-9. 2005..The advent of new strategies for pathogen reduction has raised the question of whether platelet (PLT) concentrates (PCs) exposed to longer periods of storage retain adequate hemostatic function... - Role of the geneticist in testing and counseling for inherited thrombophiliaLaura M Reich
Vascular Medicine Program, University of Minnesota Medical School, Minneapolis, Minnesota, USA
Genet Med 5:133-43. 2003.... - Increased microparticle tissue factor activity in cancer patients with Venous ThromboembolismDavid A Manly
Division of Hematology Oncology, Department of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7035, USA
Thromb Res 125:511-2. 2010..7+/-3.8 pg/mL vs 0.6+/-0.4 pg/mL, p<0.05). Further prospective studies are required to determine if levels of MP TF activity may be a useful biomarker to identify patients at increased risk for VTE... - Studies on the mechanism of action of the aptamer BAX499, an inhibitor of tissue factor pathway inhibitorJen Yea Chang
Department of Medicine, University of North Carolina at Chapel Hill, NC 27599, USA
Thromb Res 130:e151-7. 2012..These results suggest that BAX499 may be a useful addition to the armamentarium of bypassing agents to control bleeding in hemophilic patients with inhibitors... - Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon systemJohn R Ohlfest
Department of Genetics, Cell Biology, and Development, University of Minnesota Cancer Center, Arnold and Mabel Beckman Center for Transposon Research, University of Minnesota, 6 160 Jackson Hall, 321 Church St SE, Minneapolis, MN 55455, USA
Blood 105:2691-8. 2005..Thus, SB provides a nonviral means for sustained FVIII gene delivery in a mouse model of hemophilia A if the immune response is prevented... - Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipientsMilena Elimelakh
Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA
Haematologica 92:1029-36. 2007..We report a high incidence of RCA and autoimmune hemolytic anemia (AIHA) in pancreas transplant recipients on alemtuzumab-based maintenance therapy... - Platelet microparticles are heterogeneous and highly dependent on the activation mechanism: studies using a new digital flow cytometerSilvia Perez Pujol
Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA
Cytometry A 71:38-45. 2007..Platelet-derived microparticles (MPs) are believed to play an important role in coagulation and inflammatory disorders. Unfortunately, MP size renders them difficult to study and analyze by conventional flow cytometry... - Lupus anticoagulant associated with transient severe factor X deficiency: a report of two patients presenting with major bleeding complicationsAneel A Ashrani
Department of Medicine, Division of Hematology, Oncology and Transplantation, and Department of Laboratory Medicine and Pathology of the University of Minnesota Medical School, Minneapolis, MN 55455, USA
Br J Haematol 121:639-42. 2003..We conclude that patients with LA may rarely present with severe acquired FX deficiency. This may be another mechanism whereby patients with antiphospholipid antibodies present with bleeding complications... - Acquired hemophilia in malignancyBrandi N Reeves
Department of Medicine, Division of Hematology Oncology, University of North Carolina at Chapel Hill, NC, USA
Thromb Res 129:S66-8. 2012..However, appropriate consideration should be given to the choice of agents, depending on individual risk factors for complications such as thrombosis and infection... - Platelet tissue factor: how did it get there and is it important?Nigel S Key
Department of Medicine, Division of Hematology Oncology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA
Semin Hematol 45:S16-20. 2008..This brief review will summarize the state-of-the-art understanding on the origins and possible role of platelet TF... - Current treatment of venous thromboembolismNigel S Key
Harold R Roberts Distinguished Professor, Division of Hematology Oncology, Department of Medicine, 932 Mary Ellen Jones Bldg, CB 7035, Chapel Hill, NC 27599, USA
Arterioscler Thromb Vasc Biol 30:372-5. 2010..In this review, we discuss some of the issues that we believe are among the most critical unanswered questions in the management of venous thromboembolism in the present era... - Measurement of bleeding severity: a critical reviewRachel Koreth
Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis 55455, USA
Transfusion 44:605-17. 2004 - Tissue factor and its measurement in whole blood, plasma, and microparticlesNigel S Key
Division of Hematology Oncology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599, USA
Semin Thromb Hemost 36:865-75. 2010..We comment on some of the crucial preanalytical and analytical variables that influence the results and their interpretation... - Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytesArun S Shet
Vascular Biology Center, University of Minnesota Medical School, Minneapolis, USA
Blood 102:2678-83. 2003..01 for both). These data support the concept that SCD is an inflammatory state with monocyte and endothelial activation and abnormal TF activity... - Do inherited hypercoagulable states play a role in thrombotic events affecting kidney/pancreas transplant recipients?Horacio E Adrogue
Department of Medicine, O Brien Kidney Research Center, Baylor College of Medicine, Methodist Hospital, Houston, TX, USA
Clin Transplant 21:32-7. 2007..Pancreas graft thrombosis remains the leading non-immunologic cause of graft loss after pancreas transplantation. We studied the role of hypercoagulable states (HCS) in pancreas graft thrombosis (pthx)... - Analysis of individual platelet-derived microparticles, comparing flow cytometry and capillary electrophoresis with laser-induced fluorescence detectionGuohua Xiong
Department of Chemistry, Institute of Technology, University of Minnesota, Minneapolis, MN 55455, USA
Analyst 128:581-8. 2003..This is the first time that a direct comparison between these two techniques is reported... - Venous thromboembolism in multiple myeloma: current perspectives in pathogenesisNoppacharn Uaprasert
Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Eur J Cancer 46:1790-9. 2010..These studies may not only yield greater insight into the pathogenesis of disease but may also define novel targets for the prevention and treatment of thromboembolic events in patients with multiple myeloma... - Possible synergy between recombinant factor VIIa and prothrombin complex concentrate in hemophilia therapyNigel S Key
Department of Medicine, University of Minnesota, Minneapolis, USA
Thromb Haemost 88:60-5. 2002..Results with other patients supported this hypothesis. With further evaluation, a therapeutic approach combining sequential PCC and rFVIIa may prove useful for treatment of bleeding refractory to either agent used alone... - High prevalence of sickle cell trait in African Americans with ESRDVimal K Derebail
Department of Medicine, Division of Nephrology and Hypertension, University of North Carolina Kidney Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7155, USA
J Am Soc Nephrol 21:413-7. 2010..The potential effect of HbAS on the development and progression of CKD and its effect on the course and management of patients with ESRD deserve further study... - Membrane microparticles in VTE and cancerNigel S Key
Department of Medicine, Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Thromb Res 125:S80-3. 2010..The results of prospective clinical studies that are currently underway should clarify any causative relationship... - Plasma protein profiling: unique and stable features of individualsGary L Nelsestuen
Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN 55455, USA
Proteomics 5:4012-24. 2005.... - The White platelet syndrome: a new autosomal dominant platelet disorderJames G White
Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA
Platelets 15:173-84. 2004..However, gray platelets were not present among their circulating cells. The WPS is a unique autosomal dominant condition that can be classified among the platelet granule deficiency disorders... - Cytokine production by CD4+ T cells specific for coagulation factor VIII in healthy subjects and haemophilia A patientsGenlin Hu
Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, 6 155 Jackson Hall, 321 Church Street SE, Minneapolis, MN 55455, USA
Thromb Haemost 97:788-94. 2007..The polarized high ratios of Th3/Th1 and Th3/Th2 in controls and patients without inhibitors suggest that a preponderance ofTh3 cells in the response to fVIII may help to maintain tolerance to fVIII... - Platelet factor 4 enhances generation of activated protein C in vitro and in vivoArne Slungaard
Department of Medicine, Section of Hematology, Oncology and Transplantation, University of Minnesota, Mayo Mail Code 480, 420 Delaware St SE, Minneapolis, MN 55455, USA
Blood 102:146-51. 2003..These findings suggest that PF4 may play a previously unsuspected physiologic role in enhancing APC generation... - Is homozygosity for the HR2 haplotype a risk factor for venous thromboembolism?Omer Aras
Thromb Haemost 87:173-4. 2002 - Elevated whole-blood tissue factor procoagulant activity as a marker of restenosis after percutaneous transluminal coronary angioplasty and stent implantationEralp Tutar
Department of Cardiology, Ankara University School of Medicine, Ankara, Turkey
Circulation 108:1581-4. 2003..In this study, we investigated the hypothesis that elevated levels of TF in the circulation contribute to the development of restenosis after percutaneous transluminal coronary angioplasty (PTCA) or stent implantation... - Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosisNigel Mackman
Department of Immunology, The Scripps Research Institute, 10550 North Torrey Pines Road, Mail Code SP30 3040, La Jolla, CA 92037, USA
Arterioscler Thromb Vasc Biol 27:1687-93. 2007..Understanding how the extrinsic pathway of blood coagulation contributes to hemostasis and thrombosis may lead to the development of safe and effective hemostatic agents and antithrombotic drugs... - Sickle cell trait and the risk of venous thromboembolism among blacksHarland Austin
Rollins School of Public Health, Emory University, Atlanta, GA, USA
Blood 110:908-12. 2007..We conclude that sickle cell trait is a risk factor for venous thromboembolism and that the proportion of venous thromboembolism among blacks attributable to the mutation is approximately 7%... - Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirinMichael W Fried
Division of Digestive Diseases, University of North Carolina, Chapel Hill 27599, USA
Hepatology 36:967-72. 2002..Adolescents treated with combination therapy had a significantly higher sustained response than adults did on the same regimen... - Tissue factor; from Morawitz to microparticlesNigel S Key
Division of Hematology Oncology, University of North Carolina at Chapel Hill, NC 27599, USA
Trans Am Clin Climatol Assoc 118:165-73. 2007..Nonetheless, ongoing research suggests that tissue factor may be a rational therapeutic target in a number of human disease states... - Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50Yi-Feng Xia
Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Graduate School of the Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China
J Immunol 173:4207-17. 2004..Notably, it had no suppressive effect on IkappaBalpha degradation, p50 and p65 nuclear translocation, or cell growth rates. Our results thus reveal a unique pharmacological mechanism of Andro's protective anti-inflammatory actions... - Coagulation factor concentrates: past, present, and futureNigel S Key
University of North Carolina School of Medicine and Harold R Roberts Comprehensive Hemophilia Diagnostic and Treatment Center, Chapel Hill, NC, USA
Lancet 370:439-48. 2007..In the future, it is likely that bioengineered recombinant proteins that have been modified to enhance pharmacokinetic properties or reduce immunogenicity, or both, will be used increasingly in clinical practice... - Recombinant FVIIa for intractable hemorrhage: more questions than answersNigel S Key
Transfusion 43:1649-51. 2003